Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Ist Teil von
The New England journal of medicine, 2015-10, Vol.373 (14), p.1318-1328
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2015
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
In two phase 3 studies, the anti–interleukin-17 receptor A monoclonal antibody brodalumab was more effective than placebo or ustekinumab in patients with moderate-to-severe psoriasis. Adverse events associated with brodalumab included neutropenia and candida infections.
Psoriasis is an inflammatory skin disease that occurs in 2 to 3% of the worldwide population.
1
,
2
Despite the availability of several therapies, many patients remain untreated, do not have an adequate response, or have treatment-related toxic effects.
3
Interleukin-17 cytokines have been implicated in the pathogenesis of psoriasis. Genomewide association studies have linked interleukin-17 pathway–related genes with psoriasis,
4
,
5
and interleukin-17 mRNA levels are higher in psoriatic lesions than in normal skin.
6
,
7
Numbers of type 17 helper T cells are increased in psoriatic lesions and are stimulated by interleukin-23 to release interleukin-17 cytokines.
8
Interleukin-17 cytokines, which include interleukin-17A, interleukin-17C, . . .